Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 8998-9016
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8998
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8998
Table 1 Classification of hepatitis B vaccine prevention strategies
Universal vaccination alone | Universal vac. + pregnant-women screening + HBIG | Selective vaccination + pregnant-women screening + HBIG | |
Low- and intermediate-income countries1 | √ | ||
High-and intermediate-income countries1 | √ | ||
(e.g., European countries, United States) | |||
High-income countries (e.g., Scandinavian countries, United Kingdom, Japan) | √ |
Table 2 Hepatitis B surface antigen prevalence before and after the introduction of universal vaccination for hepatitis B virus
Ref. | Region | Country | Subjects | Year of the introduction of infant universal vaccination | HBsAg positive rate | ||||
Before-vaccination program | Year | After vaccination program | Year | ||||||
95 | North America | United States | (Hawai) | School children | 1992 | 1.6% | 1989 | 0.04% | 2001-2002 |
96 | South America | Colombia | (Colombian Amazon) | 5-9 yr of age | 1992 | 7% | 1992 | 2% | 1999 |
97 | Asia | Taiwan | (Taipei) | ≤ 12 yr of age | 1984 | 9.8% | 1984 | 1.3% | 1994 |
94 | Asia | China | Young children | 1992 | 9%-12% | 1992 | < 1% | 2005 | |
98 | Europe | Italy | (Afragola) | General population | 1991 | 13.4% | 1978 | 0.91% | 2006 |
99 | Africa | South Africa | (Gauteng Province) | ≤ 24 mo after birth | 1995 | 8%-9% | 1995-1996 | 0.9% | 2003-2004 |
100 | Africa | Gambia | (Keneba) | ≤ 24 yr of age | 1984 | 13.3% | 1984 | 0.6% | 2003 |
100 | Africa | Gambia | (Mandar) | ≤ 24 yr of age | 1984 | 35% | 1984 | 1% | 2003 |
Table 3 Incidence of acute hepatitis B before and after the introduction of universal vaccination for hepatitis B virus
Ref. | Region | Country | Subjects | Year of the introduction of universal vaccination | Annual incidence of acute hepatitis B cases per 100000 population | |||
Before vaccination program | Year | After vaccination program | Year | |||||
101 | North America | United States | 0-19 yr of age | 1992 | 3 | 1990 | 0.3 | 2002 |
102 | United States (Alaska) | Under 20 yr of age | 1984 | 19 | 1981-1920 | 0 | 1993-1994 | |
103 | Asia | Taiwan | Infants | 1984 | 5.36 | 1975-1984 | 1.71 | 1993-1994 |
104 | Europe | Italy | General population | 1991 | 5.1 | 1991 | 1.3 | 2005 |
Table 4 Incidence of hepatocellular carcinoma before and after the introduction of universal vaccination for hepatitis B virus
Ref. | Country | Subjects | Year of the introduction of universal vaccination | Annual incidence of HCC cases per 100000 population | |||
Before vaccination program | Year | After vaccination program | Year | ||||
102 | United States (Alaska) | Under 20 yr of age | 1984 | 3 | 1984-1988 | 0 | 1995-1999 |
109 | Taiwan | 6-14 yr of age | 1984 | 0.7 | 1981-1986 | 0.36 | 1990-1994 |
109 | Taiwan | 6-9 yr of age | 1984 | 0.52 | 1974-1984 | 0.13 | 1984-1986 |
- Citation: Komatsu H. Hepatitis B virus: Where do we stand and what is the next step for eradication? World J Gastroenterol 2014; 20(27): 8998-9016
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/8998.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.8998